  World News (13)
  World Earnings (156)
 USA (336)
 California (187)
 Bay Area (12)
Bay Area Earnings (333)
 Genentech (71)
  Business
 Earnings (21)
 1st Quarter Earnings (2)
 4th Quarter Earnings (2)
Cancer Drug Sales (2)
Rituxan (2)
 2008 (1)
2007 (2)
2006 (4)
2005 (5)
2004 (3)
2003 (2)
2002 (3)
2001 (1)
 Earnings on Wikipedia
 Earnings on Web
|
|
|
| Jan.14 |
|
4Q Profit Rises 6 Percent| The biotech giant barely scraped past expectations as stock dropped in after-hours trading as sales of a key product also fell below expectations | |
|
|
| Oct.16 |
|
3Q Profit Up 21 % On Cancer Drug Sales| The profit rose nearly 21% from a year ago, beating expectations by a penny thanks to stronger-than-expected sales of the Avastin | |
|
| Jan.10 |
|
4Q Earnings Soar 75%| A strong demand for cancer-fighting drugs fueled a profit increase as company executives shook off doubts | |
|
|
| Jul.11 |
|
2Q Profit Soars to $531 Million| The biotechnology company blew past Wall Street expectations with a 79% surge in second quarter earnings | |
|
| Apr.12 |
|
Profit climbs by 48% in first quarter Genentech Inc. raised its full-year earnings growth estimate to as much as 55% over 2005
|
| Jan.12 |
|
Shares tumble Shares dropped more than 4% as investors reacted to an earnings report that met analysts' expectations
|
| Jan.11 |
|
Up 64% in quarter after good year Earnings per share grew 63 percent to 31 cents as cancer drugs continued to build sales
|
|
| Oct.10 |
|
Big 3rd Quarter Gains Genentech Inc. reported a 56% surge in 3rd-quarter net income, fueled by drug sales of its colon cancer drug
|
| Jul.11 |
|
Profits Soar 73% in 2Q| The second quarter profit is fueled by continued strong drug sales. The results exceeded the estimate by 4 cents | |
|
| May.24 |
|
Genentech up on drug data Drug for a eye disease showed that it may stabilize or reverse the condition in a clinical trial
|
| Apr.12 |
|
Biotech giant's profit up 61% The colon cancer drug Avastin and other cancer drugs boost sales
|
| Jan.10 |
|
Profit surges, misses expectations by 1c Biotechnology titan reported a 63% surge in its fourth-quarter profits on strong sales of a string of new drugs
|
|
| Oct.6 |
|
Profits surge on drug sales Genentech reported a 52% surge in 3rd-quarter net income, fueled by strong drug sales across its product line
|
| Apr.7 |
|
Profits surge on brisk cancer drug sales Biotechnology company yearlong hot streak continued when it reported robust profits for the first quarter
|
| Jan.14 |
|
Profits surge on strong drug sales The results, lifted by popular cancer-fighting drugs, beat analysts' expectations
|
|
| Oct.8 |
|
Biotech titan posts higher profits Genentech is boosted by continued strong sales of its 2 blockbuster cancer-fighting drugs and a one-time legal settlement
|
| Jan.15 |
|
Reports continued strong earnings Profit in the fourth quarter more than doubled, but a $500 million legal setback detracted from an otherwise rosy year
|
|
| Aug.15 |
|
Ex-employee charged with insider trading Lei Wang, 32, a former Genentech programmer has agreed to pay $76,000 to settle charges
|
| Apr.5 |
|
Stock falls Biotechnology titan warned it is not ready to apply for federal approval to sell the psoriasis drug Xanelim
|
| Jan.16 |
|
Earnings rise Biotechnology company nearly tripled its earnings on the sales strength of its two cancer drugs
|
|
| Oct.10 |
|
Profits rise 3rd quarter profits rose sixfold. The results exceeded expectations. Net income is $42.7 million
|
|
Add a favorite (file a bookmark) to Genentech, Earnings Timeline
Please send feedback to: support@mapreport.com
Advertise on Genentech, Earnings Page
XML
|
